Ernexa Therapeutics (ERNAW) EBITDA Margin (2010 - 2024)
Ernexa Therapeutics (ERNAW) reported EBITDA Margin of 14194.74% for Q4 2024, down 242943.0% on a YoY basis from N/an in Q1 2024, and down 2960.13% quarter-over-quarter from 463.86% in Q3 2024.
Ernexa Therapeutics (ERNAW) EBITDA Margin (2010 - 2024) Analysis & Trends
Ernexa Therapeutics has reported EBITDA Margin for 13 years, with the latest figure at 14194.74% in Q4 2024.
- For the quarter ending Q4 2024, EBITDA Margin fell 242943.0% year-over-year to 14194.74%; the trailing twelve-month figure through Dec 2024 stood at 2612.33% (up 1852267.0% YoY), and the FY2024 full-year result was 2612.33%, up 1852267.0% from the prior year.
- EBITDA Margin for Q4 2024 stood at 14194.74%, down from 463.86% in the prior quarter.
- The five-year high for EBITDA Margin was 26.47% in Q4 2020, with the low at 14194.74% in Q4 2024.
- Historically, EBITDA Margin has averaged 6683.47% across 3 years, with a median of 10491.49% in 2024.
- The largest YoY upside for EBITDA Margin was 1033026 bps in 2024 against a maximum downside of 242943 bps in 2024.
- Ernexa Therapeutics' EBITDA Margin stood at 26.47% in 2020, then plunged by 44551 bps to 11765.31% in 2023, then fell by 21 bps to 14194.74% in 2024.
- The last three EBITDA Margin figures came in at 14194.74% (Q4 2024), 463.86% (Q3 2024), and 10491.49% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ernexa Therapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -14,194.74% |
| Sep 30, 2024 | -463.86% |
| Jun 30, 2024 | -10,491.49% |
| Mar 31, 2024 | -12,312.77% |
| Dec 31, 2023 | -11,765.31% |
| Sep 30, 2023 | -10,794.12% |
| Dec 31, 2020 | 26.47% |
| Sep 30, 2020 | -100.20% |
| Mar 31, 2020 | -55.22% |
| Dec 31, 2019 | -24.61% |
| Sep 30, 2019 | -8.06% |
| Jun 30, 2019 | -1.11% |
| Mar 31, 2019 | -5.79% |
| Dec 31, 2018 | -0.69% |
| Sep 30, 2018 | 4.35% |
| Jun 30, 2018 | -2.96% |
| Mar 31, 2018 | -7.93% |
| Dec 31, 2017 | -7.65% |
| Sep 30, 2017 | -2.00% |
| Jun 30, 2017 | -2.22% |